{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T08:33:10Z","timestamp":1789115590589,"version":"build-2803163510"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"DOI":"10.1007\/s11899-026-00788-z","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T07:44:11Z","timestamp":1789112651000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Strategies to Overcome Inequities in the Treatment of Patients with Hematologic Malignancies"],"prefix":"10.1007","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6091-6374","authenticated-orcid":false,"given":"Carlos","family":"de la Cruz-de la Cruz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3261-4129","authenticated-orcid":false,"given":"Yessica M.","family":"Gonz\u00e1lez-M\u00e1rtinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6904-9345","authenticated-orcid":false,"given":"Andr\u00e9s","family":"G\u00f3mez-De Le\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,11]]},"reference":[{"key":"788_CR1","unstructured":"World Health Organization. Global tuberculosis control 2011. Geneva: World Health Organization. 2011. Available from: http:\/\/www.who.int\/tb\/publications\/global_report\/2011\/gtbr11_full.pdf"},{"issue":"8","key":"788_CR2","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nrc1948","volume":"6","author":"DM Parkin","year":"2006","unstructured":"Parkin DM. The evolution of the population-based cancer registry. Nat Rev Cancer. 2006;6(8):603\u201312.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"788_CR3","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41408-023-00853-3","volume":"13","author":"N Zhang","year":"2023","unstructured":"Zhang N, Wu J, Wang Q, Liang Y, Li X, Chen G, et al. Global burden of hematologic malignancies and evolution patterns over the past 30 years. Blood Cancer J. 2023;13(1):82.","journal-title":"Blood Cancer J"},{"key":"788_CR4","unstructured":"World Health Organization. World malaria report 2010. Geneva: World Health Organization. 2010. Available from: http:\/\/www.who.int\/malaria\/publications\/atoz\/9789241564106\/en\/index.html"},{"key":"788_CR5","unstructured":"Ferlay J, Laversanne M, Ervik M, Lam F, Colombet M, Mery L et al. Global Cancer Observatory: Cancer Tomorrow. Version 1.1. Lyon: International Agency for Research on Cancer. Available from: https:\/\/gco.iarc.who.int\/tomorrow"},{"issue":"9747","key":"788_CR6","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1016\/S0140-6736(10)61152-X","volume":"376","author":"P Farmer","year":"2010","unstructured":"Farmer P, Frenk J, Knaul FM, Shulman LN, Alleyne G, Armstrong L, et al. Expansion of cancer care and control in countries of low and middle income: a call to action. Lancet. 2010;376(9747):1186\u201393.","journal-title":"Lancet"},{"issue":"3","key":"788_CR7","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1182\/blood-2018-04-844472","volume":"132","author":"S Gopal","year":"2018","unstructured":"Gopal S, Gross TG. How I treat Burkitt lymphoma in children, adolescents, and young adults in sub-Saharan Africa. Blood. 2018;132(3):254\u201363.","journal-title":"Blood"},{"issue":"12","key":"788_CR8","doi-asserted-by":"publisher","first-page":"e1715","DOI":"10.1016\/S2214-109X(22)00429-6","volume":"10","author":"GBD 2019 Healthcare Access and Quality Collaborators","year":"2022","unstructured":"GBD 2019 Healthcare Access and Quality Collaborators. Assessing performance of the Healthcare Access and Quality Index, overall and by select age groups, for 204 countries and territories, 1990\u20132019: a systematic analysis from the Global Burden of Disease Study 2019. Lancet Glob Health. 2022;10(12):e1715\u201343. https:\/\/doi.org\/10.1016\/S2214-109X(22)00429-6.","journal-title":"Lancet Glob Health"},{"key":"788_CR9","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1186\/s12916-015-0433-1","volume":"13","author":"M Kimman","year":"2015","unstructured":"Kimman M, Jan S, Yip CH, ACTION Study Group, et al. Catastrophic health expenditure and 12-month mortality associated with cancer in Southeast Asia: results from a longitudinal study in eight countries. BMC Med. 2015;13:190.","journal-title":"BMC Med"},{"key":"788_CR10","doi-asserted-by":"publisher","first-page":"437971","DOI":"10.1155\/2014\/437971","volume":"2014","author":"AS Ibrahim","year":"2014","unstructured":"Ibrahim AS, Khaled HM, Mikhail NNH, Baraka H, Kamel H. Cancer incidence in Egypt: results of the national population-based cancer registry program. J Cancer Epidemiol. 2014;2014:437971.","journal-title":"J Cancer Epidemiol"},{"issue":"6","key":"788_CR11","doi-asserted-by":"publisher","first-page":"422","DOI":"10.26719\/2017.23.6.422","volume":"23","author":"S Abdelmabood","year":"2017","unstructured":"Abdelmabood S, Kandil S, Megahed A, Fouda A. Delays in diagnosis and treatment among children with cancer: Egyptian perspective. East Mediterr Health J. 2017;23(6):422\u20139.","journal-title":"East Mediterr Health J"},{"key":"788_CR12","doi-asserted-by":"publisher","first-page":"14","DOI":"10.64943\/ljmas.v1i1.3","volume":"1","author":"DP Wal","year":"2023","unstructured":"Wal DP, Saed A, Almahtout AM, Ahmed SA. A multidisciplinary exploration of diseases, treatments, and impact, from cancer-related anemia to pandemics and therapeutics. Libyan J Med Appl Sci. 2023;1:14\u201330.","journal-title":"Libyan J Med Appl Sci"},{"issue":"1","key":"788_CR13","first-page":"1","volume":"1","author":"A Lucas","year":"2024","unstructured":"Lucas A. Chronic disease management in low-resource settings: challenges, innovations, and pathways to equity. Public Health Spectr. 2024;1(1):1.","journal-title":"Public Health Spectr"},{"issue":"1","key":"788_CR14","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/s12939-023-01992-6","volume":"22","author":"P Filippone","year":"2023","unstructured":"Filippone P, Serrano S, Campos S, et al. Understanding why racial\/ethnic inequities along the HIV care continuum persist in the United States: a qualitative exploration of systemic barriers from the perspectives of African American\/Black and Latino persons living with HIV. Int J Equity Health. 2023;22(1):168.","journal-title":"Int J Equity Health"},{"key":"788_CR15","doi-asserted-by":"publisher","first-page":"3885979","DOI":"10.1155\/2022\/3885979","volume":"2022","author":"WI Egesa","year":"2022","unstructured":"Egesa WI, Nakalema G, Waibi WM, et al. Sickle cell disease in children and adolescents: a review of the historical, clinical, and public health perspective of sub-Saharan Africa and beyond. Int J Pediatr. 2022;2022:3885979.","journal-title":"Int J Pediatr"},{"key":"788_CR16","doi-asserted-by":"publisher","first-page":"1388855","DOI":"10.3389\/fresc.2024.1388855","volume":"5","author":"PM Boma","year":"2024","unstructured":"Boma PM, Ngoy SKK, Panda JM, Bonnech\u00e8re B. Empowering sickle cell disease care: the rise of Technorehablab in sub-Saharan Africa for enhanced patient\u2019s perspectives. Front Rehabil Sci. 2024;5:1388855.","journal-title":"Front Rehabil Sci"},{"issue":"4","key":"788_CR17","doi-asserted-by":"publisher","first-page":"e564","DOI":"10.1200\/OP.21.00420","volume":"18","author":"T Dosani","year":"2022","unstructured":"Dosani T, Xiang J, Wang K, et al. Impact of hematology electronic consultations on utilization of referrals and patient outcomes in an integrated health care system. JCO Oncol Pract. 2022;18(4):e564\u201373. https:\/\/doi.org\/10.1200\/OP.21.00420.","journal-title":"JCO Oncol Pract"},{"key":"788_CR18","unstructured":"Futrell K. The value of the laboratory in the new healthcare model: diagnostic information, the new currency in the future of healthcare. ASCP; 2013. Available from: http:\/\/www.orchardsoft.com\/files\/white_paper_value_lab.pdf"},{"key":"788_CR19","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s40291-025-00775-9","volume":"29","author":"DG Gupta","year":"2025","unstructured":"Gupta DG, Monika, Varma N. Bridging the gap: cost-effective strategies for detecting Ph-like B-lineage ALL in resource-limited settings. Mol Diagn Ther. 2025;29:329\u201344.","journal-title":"Mol Diagn Ther"},{"issue":"6","key":"788_CR20","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.clml.2026.03.008","volume":"26","author":"R de C\u00e1ssia Cavaglieri","year":"2026","unstructured":"de C\u00e1ssia Cavaglieri R, Nardinelli L, Rijken M, et al. SOHO State of the Art Updates and Next Questions: implementing next-generation sequencing (NGS) in resource-constrained settings: the experience of the International Consortium on Acute Leukemias (ICAL). Clin Lymphoma Myeloma Leuk. 2026;26(6):351\u2013e61. https:\/\/doi.org\/10.1016\/j.clml.2026.03.008.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"788_CR21","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-025-04215-2","author":"Y Yousafzai","year":"2026","unstructured":"Yousafzai Y, Mir A, Hameed M, Khan SN, Mushtaq H, Islam M. Optimizing limited antibody panels for efficient hematological disorders diagnosis by flow cytometry in resource-constrained setting. Clin Transl Oncol. 2026. https:\/\/doi.org\/10.1007\/s12094-025-04215-2.","journal-title":"Clin Transl Oncol"},{"issue":"5","key":"788_CR22","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1038\/leu.2013.293","volume":"28","author":"H Ludwig","year":"2014","unstructured":"Ludwig H, Miguel JS, Dimopoulos MA, et al. International Myeloma Working Group recommendations for global myeloma care. Leukemia. 2014;28(5):981\u201392. https:\/\/doi.org\/10.1038\/leu.2013.293.","journal-title":"Leukemia"},{"key":"788_CR23","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1200\/GO.20.00436","volume":"6","author":"BO Anderson","year":"2020","unstructured":"Anderson BO. NCCN Harmonized Guidelines for sub-Saharan Africa: a collaborative methodology for translating resource-adapted guidelines into actionable in-country cancer control plans. JCO Glob Oncol. 2020;6:1419\u201321. https:\/\/doi.org\/10.1200\/GO.20.00436.","journal-title":"JCO Glob Oncol"},{"key":"788_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JGO.18.00113","volume":"4","author":"S Al-Sukhun","year":"2018","unstructured":"Al-Sukhun S, Temin S, Chavez-MacGregor M, et al. ASCO resource-stratified guidelines: methods and opportunities. J Glob Oncol. 2018;4:1\u20138. https:\/\/doi.org\/10.1200\/JGO.18.00113.","journal-title":"J Glob Oncol"},{"key":"788_CR25","doi-asserted-by":"publisher","first-page":"243","DOI":"10.3389\/fonc.2016.00243","volume":"6","author":"A Garg","year":"2016","unstructured":"Garg A, Morgunskyy M, Belagali Y, et al. Management of multiple myeloma and usage of bortezomib: perspective from India and Ukraine. Front Oncol. 2016;6:243. https:\/\/doi.org\/10.3389\/fonc.2016.00243.","journal-title":"Front Oncol"},{"issue":"9","key":"788_CR26","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1002\/cncr.31305","volume":"124","author":"L Tar\u00edn-Arzaga","year":"2018","unstructured":"Tar\u00edn-Arzaga L, Arredondo-Campos D, Mart\u00ednez-Pacheco V, et al. Impact of the affordability of novel agents in patients with multiple myeloma: real-world data of current clinical practice in Mexico. Cancer. 2018;124(9):1946\u201353. https:\/\/doi.org\/10.1002\/cncr.31305.","journal-title":"Cancer"},{"issue":"2","key":"788_CR27","doi-asserted-by":"publisher","first-page":"e71","DOI":"10.1016\/j.clml.2024.08.007","volume":"25","author":"E Kastritis","year":"2025","unstructured":"Kastritis E, Beksac M, Badelita SN, et al. VCd versus VRd in newly diagnosed multiple myeloma: matched real-world analysis from the Balkan Myeloma Study Group (BMSG). Clin Lymphoma Myeloma Leuk. 2025;25(2):e71\u201381. https:\/\/doi.org\/10.1016\/j.clml.2024.08.007.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"788_CR28","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1053\/j.seminoncol.2016.11.012","volume":"43","author":"L Kumar","year":"2016","unstructured":"Kumar L, Sahoo RK. Management of multiple myeloma in resource-constrained settings. Semin Oncol. 2016;43(6):690\u20134. https:\/\/doi.org\/10.1053\/j.seminoncol.2016.11.012.","journal-title":"Semin Oncol"},{"key":"788_CR29","doi-asserted-by":"publisher","DOI":"10.1200\/OP-25-00947","author":"PG Roy","year":"2026","unstructured":"Roy PG, Gogia A, Anwar Z, Mukherjee S, Anwer F. Multiple myeloma management in a large low- and middle-income country: lessons from India in balancing cost and clinical efficacy in resource-limited settings. JCO Oncol Pract. 2026. https:\/\/doi.org\/10.1200\/OP-25-00947.","journal-title":"JCO Oncol Pract"},{"issue":"12","key":"788_CR30","doi-asserted-by":"publisher","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"W Hiddemann","year":"2005","unstructured":"Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005;106(12):3725\u201332.","journal-title":"Blood"},{"issue":"9873","key":"788_CR31","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","volume":"381","author":"MJ Rummel","year":"2013","unstructured":"Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381(9873):1203\u201310.","journal-title":"Lancet"},{"issue":"11","key":"788_CR32","doi-asserted-by":"publisher","first-page":"2674","DOI":"10.1002\/ijc.29635","volume":"137","author":"RB Lim","year":"2015","unstructured":"Lim RB, Loy EY, Lim GH, Zheng H, Chow KY, Lim ST. Gender and ethnic differences in incidence and survival of lymphoid neoplasm subtypes in an Asian population: secular trends of a population-based cancer registry from 1998 to 2012. Int J Cancer. 2015;137(11):2674\u201387.","journal-title":"Int J Cancer"},{"key":"788_CR33","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1200\/GO.21.00320","volume":"7","author":"R Iftikhar","year":"2021","unstructured":"Iftikhar R, Mir MA, Moosajee M, et al. Diagnosis and management of diffuse large B-cell lymphoma: Society of Medical Oncology Pakistan, Pakistan Society of Hematology, and Pakistan Society of Clinical Oncology joint clinical practice guideline. JCO Glob Oncol. 2021;7:1647\u201358. https:\/\/doi.org\/10.1200\/GO.21.00320.","journal-title":"JCO Glob Oncol"},{"issue":"2","key":"788_CR34","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1080\/1750743X.2026.2639275","volume":"18","author":"H Numan","year":"2026","unstructured":"Numan H, Tfayli A. Financial barriers to immunotherapy: challenges and potential mitigation strategies: a review paper. Immunotherapy. 2026;18(2):89\u201397. https:\/\/doi.org\/10.1080\/1750743X.2026.2639275.","journal-title":"Immunotherapy"},{"issue":"12","key":"788_CR35","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1182\/blood.2024023890","volume":"144","author":"LCDA Koury","year":"2024","unstructured":"Koury LCDA, Kim HT, Undurraga MS, et al. Clinical networking results in continuous improvement of the outcome of patients with acute promyelocytic leukemia. Blood. 2024;144(12):1257\u201370. https:\/\/doi.org\/10.1182\/blood.2024023890.","journal-title":"Blood"},{"key":"788_CR36","doi-asserted-by":"publisher","first-page":"100593","DOI":"10.1016\/j.lansea.2025.100593","volume":"37","author":"MP Gogoi","year":"2025","unstructured":"Gogoi MP, Das P, Das N, et al. Risk stratified treatment for childhood acute lymphoblastic leukaemia: a multicentre observational study from India. Lancet Reg Health Southeast Asia. 2025;37:100593. https:\/\/doi.org\/10.1016\/j.lansea.2025.100593.","journal-title":"Lancet Reg Health Southeast Asia"},{"issue":"19","key":"788_CR37","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","volume":"369","author":"JE Cortes","year":"2013","unstructured":"Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013;369(19):1783\u201396. https:\/\/doi.org\/10.1056\/NEJMoa1306494.","journal-title":"N Engl J Med"},{"key":"788_CR38","doi-asserted-by":"publisher","first-page":"e2400538","DOI":"10.1200\/GO-24-00538","volume":"11","author":"HA Vaquera-Alfaro","year":"2025","unstructured":"Vaquera-Alfaro HA, Montelongo-Cepeda JE, Vega-Mateos A, Morales-Pedraza A, Verduzco-Aguirre H, G\u00f3mez-Almaguer D, et al. Low-dose anti-PD1 immune checkpoint inhibitors in relapsed\/refractory Hodgkin lymphoma: a systematic review. JCO Glob Oncol. 2025;11:e2400538. https:\/\/doi.org\/10.1200\/GO-24-00538.","journal-title":"JCO Glob Oncol"},{"key":"788_CR39","doi-asserted-by":"publisher","first-page":"107373","DOI":"10.1016\/j.leukres.2023.107373","volume":"133","author":"F De la Garza-Salazar","year":"2023","unstructured":"De la Garza-Salazar F, Colunga-Pedraza PR, G\u00f3mez-Almaguer D, Garc\u00eda-Z\u00e1rate VA, G\u00f3mez-De Le\u00f3n A. Low-dose venetoclax plus itraconazole outpatient induction in newly diagnosed acute myeloid leukemia: a phase 2 study. Leuk Res. 2023;133:107373. https:\/\/doi.org\/10.1016\/j.leukres.2023.107373.","journal-title":"Leuk Res"},{"key":"788_CR40","doi-asserted-by":"publisher","first-page":"e2500469","DOI":"10.1200\/GO-25-00469","volume":"12","author":"JE Colunga Pedraza","year":"2026","unstructured":"Colunga Pedraza JE, G\u00f3mez-De Le\u00f3n A, Colunga Pedraza PR, L\u00f3pez Reyna IG, Mart\u00ednez Mart\u00ednez CG, Jim\u00e9nez Antolinez YV, et al. Optimizing blinatumomab access for low- and middle-income countries: feasibility of a shortened, vial-sharing, outpatient approach for pediatric ALL. JCO Glob Oncol. 2026;12:e2500469. https:\/\/doi.org\/10.1200\/GO-25-00469.","journal-title":"JCO Glob Oncol"},{"issue":"1","key":"788_CR41","doi-asserted-by":"publisher","first-page":"100045","DOI":"10.1016\/j.bglo.2025.100045","volume":"2","author":"F De la Garza-Salazar","year":"2026","unstructured":"De la Garza-Salazar F, Lopez-Garcia YK, De la Rosa-Flores A, Ugarte-Pel\u00e1ez P, Olivares-Gazca JC, Ruiz-Arg\u00fcelles GJ, et al. Outpatient low-dose venetoclax-azacitidine vs intensive therapy in newly diagnosed AML in resource-limited settings. Blood Glob Hematol. 2026;2(1):100045. https:\/\/doi.org\/10.1016\/j.bglo.2025.100045.","journal-title":"Blood Glob Hematol"},{"issue":"3","key":"788_CR42","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1182\/blood-2016-07-726307","volume":"129","author":"P Theunissen","year":"2017","unstructured":"Theunissen P, Mejstrikova E, Sedek L, et al. Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia. Blood. 2017;129(3):347\u201357.","journal-title":"Blood"},{"issue":"5","key":"788_CR43","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.3324\/haematol.2021.279189","volume":"107","author":"D Niederwieser","year":"2022","unstructured":"Niederwieser D, Baldomero H, Bazuaye N, Bupp C, Chaudhri N, Corbacioglu S, et al. One and a half million hematopoietic stem cell transplants: continuous and differential improvement in worldwide access with the use of non-identical family donors. Haematologica. 2022;107(5):1045\u201353.","journal-title":"Haematologica"},{"issue":"12","key":"788_CR44","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.1016\/j.bbmt.2019.05.002","volume":"25","author":"MC Pasquini","year":"2019","unstructured":"Pasquini MC, Srivastava A, Ahmed SO, Aljurf M, Atsuta Y, Doleysh C, et al. Worldwide Network for Blood and Marrow Transplantation recommendations for establishing a hematopoietic cell transplantation program, part I: minimum requirements and beyond. Biol Blood Marrow Transpl. 2019;25(12):2322\u20139.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"4","key":"788_CR45","doi-asserted-by":"publisher","first-page":"103707","DOI":"10.1016\/j.transci.2023.103707","volume":"62","author":"M Sawa","year":"2023","unstructured":"Sawa M, Zatorska-Kwieci\u0144ska M, Go\u017adzik J. Optimizing of the isolation of hematopoietic stem cell in bone marrow transplantation in children. Transfus Apher Sci. 2023;62(4):103707. https:\/\/doi.org\/10.1016\/j.transci.2023.103707.","journal-title":"Transfus Apher Sci"},{"key":"788_CR46","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.socscimed.2018.01.026","volume":"200","author":"P van Baal","year":"2018","unstructured":"van Baal P, Morton A, Severens JL. Health care input constraints and cost effectiveness analysis decision rules. Soc Sci Med. 2018;200:59\u201364. https:\/\/doi.org\/10.1016\/j.socscimed.2018.01.026.","journal-title":"Soc Sci Med"},{"issue":"4","key":"788_CR47","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1177\/0272989X211053792","volume":"42","author":"SJ Wright","year":"2022","unstructured":"Wright SJ, Newman WG, Payne K. Quantifying the impact of capacity constraints in economic evaluations: an application in precision medicine. Med Decis Mak. 2022;42(4):538\u201353. https:\/\/doi.org\/10.1177\/0272989X211053792.","journal-title":"Med Decis Mak"},{"key":"788_CR48","unstructured":"Cancer Care Ontario. Acute Leukemia Shared-Care Program in the Greater Toronto Area. Toronto: Cancer Care Ontario. Available from: https:\/\/www.cancercareontario.ca\/en\/about\/programs\/clinical-services\/specialized-services-oversight\/acute-leukemia\/greater-toronto-area"},{"key":"788_CR49","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.leukres.2017.05.023","volume":"59","author":"SA Hershenfeld","year":"2017","unstructured":"Hershenfeld SA, Maki K, Rothfels L, Murray CS, Nixon S, Schimmer AD, et al. Sharing post-AML consolidation supportive therapy with local centers reduces patient travel burden without compromising outcomes. Leuk Res. 2017;59:93\u20136.","journal-title":"Leuk Res"},{"issue":"1","key":"788_CR50","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1182\/hematology.2020000096","volume":"2020","author":"AP Jillella","year":"2020","unstructured":"Jillella AP, Cortes JE, Kota VK. Optimizing management of acute leukemia in community centers and when to refer. Hematol Am Soc Hematol Educ Program. 2020;2020(1):123\u20138. https:\/\/doi.org\/10.1182\/hematology.2020000096.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"2","key":"788_CR51","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.blre.2017.09.001","volume":"32","author":"AP Jillella","year":"2018","unstructured":"Jillella AP, Kota VK. The global problem of early deaths in acute promyelocytic leukemia: a strategy to decrease induction mortality in the most curable leukemia. Blood Rev. 2018;32(2):89\u201395.","journal-title":"Blood Rev"},{"key":"788_CR52","doi-asserted-by":"publisher","first-page":"5","DOI":"10.7812\/TPP\/20.271","volume":"25","author":"LY Law","year":"2021","unstructured":"Law LY, Uong SP, Vempaty HT, Nguyen VH, Baer D, Liu VX, et al. Regionalization of acute myeloid leukemia treatment in a community-based population: implementation and early results. Perm J. 2021;25:5.","journal-title":"Perm J"},{"key":"788_CR53","first-page":"15","volume":"1","author":"KR Muir","year":"1992","unstructured":"Muir KR, Parkes SE, Boon R, Stevens MCG, Mann JR. Shared care in paediatric oncology. J Cancer Care. 1992;1:15\u20137.","journal-title":"J Cancer Care"},{"issue":"3","key":"788_CR54","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1111\/ajr.12958","volume":"31","author":"P Slater","year":"2023","unstructured":"Slater P, Hastings Y, Nicholson J, Noyes M, Benitez L, Pollock K, et al. Fifteen years of shared care for paediatric oncology, haematology and palliative patients across Queensland: the role of regional case managers. Aust J Rural Health. 2023;31(3):436\u201351.","journal-title":"Aust J Rural Health"},{"issue":"2","key":"788_CR55","doi-asserted-by":"publisher","first-page":"165","DOI":"10.5737\/23688076312165174","volume":"31","author":"V Cheung","year":"2021","unstructured":"Cheung V, Siddiq N, Devlin R, McNamara C, Gupta V. Shared-care model for complex chronic haematological malignancies. Can Oncol Nurs J. 2021;31(2):165\u201386.","journal-title":"Can Oncol Nurs J"},{"key":"788_CR56","unstructured":"Kemler S, Lohr A. Cell and gene therapy investment outlook in 2022 and beyond. 2022. Available from: https:\/\/www.cellandgene.com\/doc\/cell-gene-therapies-investment-outlook-in-beyond-0001"},{"issue":"Suppl 4","key":"788_CR57","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1186\/s12913-017-2755-5","volume":"17","author":"JK Elrod","year":"2017","unstructured":"Elrod JK, Fortenberry JL Jr. The hub-and-spoke organization design revisited: a lifeline for rural hospitals. BMC Health Serv Res. 2017;17(Suppl 4):795. https:\/\/doi.org\/10.1186\/s12913-017-2755-5.","journal-title":"BMC Health Serv Res"},{"key":"788_CR58","doi-asserted-by":"publisher","first-page":"20","DOI":"10.2478\/jhp-2022-0003","volume":"9","author":"A Bok","year":"2022","unstructured":"Bok A, Noone D, Skouw-Rasmussen N. Key challenges for hub and spoke models of care: a report from the 1st workshop of the EHC think tank on hub and spoke treatment models. J Haemoph Pract. 2022;9:20\u20136.","journal-title":"J Haemoph Pract"},{"issue":"9","key":"788_CR59","doi-asserted-by":"publisher","first-page":"e1494","DOI":"10.1200\/OP.22.00056","volume":"18","author":"TG Knight","year":"2022","unstructured":"Knight TG, Aguiar M, Robinson M, et al. Financial toxicity intervention improves outcomes in patients with hematologic malignancy. JCO Oncol Pract. 2022;18(9):e1494\u2013504. https:\/\/doi.org\/10.1200\/OP.22.00056.","journal-title":"JCO Oncol Pract"},{"key":"788_CR60","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.3332\/ecancer.2023.1532","volume":"17","author":"M Hassan","year":"2023","unstructured":"Hassan M, Butt ZA. Applying the syndemic framework to cancer research for effective cancer control in low- and middle-income countries. Ecancermedicalscience. 2023;17:1532.","journal-title":"Ecancermedicalscience"},{"issue":"3","key":"788_CR61","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/S1470-2045(18)30076-7","volume":"19","author":"B Gyawali","year":"2018","unstructured":"Gyawali B, Sullivan R, Booth CM. Cancer groundshot: going global before going to the moon. Lancet Oncol. 2018;19(3):288\u201390.","journal-title":"Lancet Oncol"},{"issue":"1","key":"788_CR62","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s41043-025-00829-y","volume":"44","author":"Z Yang","year":"2025","unstructured":"Yang Z, Li Y, Liu S, et al. Impact of national volume-based procurement policy on drugs treating chronic myelogenous leukemia. J Health Popul Nutr. 2025;44(1):96. https:\/\/doi.org\/10.1186\/s41043-025-00829-y.","journal-title":"J Health Popul Nutr"},{"issue":"12","key":"788_CR63","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1200\/OP.22.00315","volume":"18","author":"J Mikhael","year":"2022","unstructured":"Mikhael J, Fowler J, Shah N. Chimeric antigen receptor T-cell therapies: barriers and solutions to access. JCO Oncol Pract. 2022;18(12):800\u20137.","journal-title":"JCO Oncol Pract"},{"key":"788_CR64","doi-asserted-by":"publisher","first-page":"e397912","DOI":"10.1200\/EDBK_397912","volume":"43","author":"ERS Cliff","year":"2023","unstructured":"Cliff ERS, Kelkar AH, Russler-Germain DA, et al. High cost of chimeric antigen receptor T-cells: challenges and solutions. Am Soc Clin Oncol Educ Book. 2023;43:e397912.","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"14","key":"788_CR65","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1182\/blood.2025030872","volume":"147","author":"AY Ge","year":"2026","unstructured":"Ge AY, Feldman WB, Kaiser MF, et al. Global access to commercial CAR T-cell therapies: a cross-sectional study of health technology assessment across the G20 countries. Blood. 2026;147(14):1521\u201331. https:\/\/doi.org\/10.1182\/blood.2025030872.","journal-title":"Blood"},{"key":"788_CR66","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/B978-0-443-23518-4.00012-6","volume-title":"Formulating and implementing pharmaceutical pricing policies: challenges, case studies and lessons learned from medicine price control","author":"LP Gargano","year":"2025","unstructured":"Gargano LP, Alvares-Teodoro J, Borin MC, Guerra AA Jr. How to price advanced therapies? Mixed approach for valuing a new CAR-T cell for multiple myeloma in Brazil. Formulating and implementing pharmaceutical pricing policies: challenges, case studies and lessons learned from medicine price control. Amsterdam: Elsevier; 2025. pp. 293\u2013316. https:\/\/doi.org\/10.1016\/B978-0-443-23518-4.00012-6."},{"key":"788_CR67","doi-asserted-by":"publisher","first-page":"e2400409","DOI":"10.1200\/GO-24-00409","volume":"11","author":"C Hoyek","year":"2025","unstructured":"Hoyek C, Zheng-Lin B, Bauernfeind JJ, Al-Ahmad OH, Bekaii-Saab T, Chakrabarti S, et al. Overcoming financial and access barriers in global cancer care with low-dose immunotherapy: A systematic review. JCO Glob Oncol. 2025;11:e2400409. https:\/\/doi.org\/10.1200\/GO-24-00409.","journal-title":"JCO Glob Oncol"},{"key":"788_CR68","doi-asserted-by":"publisher","first-page":"e000332","DOI":"10.1136\/esmoopen-2018-000332","volume":"3","author":"SH Yoo","year":"2018","unstructured":"Yoo SH, Keam B, Kim M, et al. Low-dose nivolumab can be effective in non-small cell lung cancer: alternative option for financial toxicity. ESMO Open. 2018;3:e000332.","journal-title":"ESMO Open"},{"key":"788_CR69","doi-asserted-by":"publisher","first-page":"e48987","DOI":"10.2196\/48987","volume":"7","author":"A Santamaria","year":"2023","unstructured":"Santamaria A, Ant\u00f3n Maldonado C, S\u00e1nchez-Qui\u00f1ones B, et al. Implementing telemedicine in clinical practice in the first Digital Hematology Unit: feasibility study. JMIR Form Res. 2023;7:e48987. https:\/\/doi.org\/10.2196\/48987.","journal-title":"JMIR Form Res"},{"issue":"2","key":"788_CR70","doi-asserted-by":"publisher","first-page":"892","DOI":"10.3390\/curroncol29020076","volume":"29","author":"A Suleman","year":"2022","unstructured":"Suleman A, Vijenthira A, Berlin A, Prica A, Rodin D. The use of virtual care in patients with hematologic malignancies: a scoping review. Curr Oncol. 2022;29(2):892\u2013900. https:\/\/doi.org\/10.3390\/curroncol29020076.","journal-title":"Curr Oncol"},{"issue":"16","key":"788_CR71","doi-asserted-by":"publisher","first-page":"4108","DOI":"10.3390\/cancers15164108","volume":"15","author":"AP Gandhi","year":"2023","unstructured":"Gandhi AP, Lee CJ. Telemedicine in hematopoietic cell transplantation and chimeric antigen receptor-T cell therapy. Cancers (Basel). 2023;15(16):4108. https:\/\/doi.org\/10.3390\/cancers15164108.","journal-title":"Cancers (Basel)"},{"issue":"4","key":"788_CR72","first-page":"207.e1","volume":"28","author":"AD Sung","year":"2022","unstructured":"Sung AD, Giri VK, Tang H, Nichols KR, Lew MV, Bohannon L, et al. Home-based hematopoietic cell transplantation in the United States. Transpl Cell Ther. 2022;28(4):207.e1-207.e8.","journal-title":"Transpl Cell Ther"},{"issue":"6","key":"788_CR73","doi-asserted-by":"publisher","first-page":"e26121","DOI":"10.2196\/26121","volume":"5","author":"A Mussetti","year":"2021","unstructured":"Mussetti A, Salas MQ, Condom M, Antonio A, Ochoa C, Ivan I, et al. Use of telehealth for domiciliary follow-up after hematopoietic cell transplantation during the COVID-19 pandemic: prospective pilot study. JMIR Form Res. 2021;5(6):e26121.","journal-title":"JMIR Form Res"},{"issue":"2","key":"788_CR74","first-page":"e1811","volume":"27","author":"A Racioppi","year":"2021","unstructured":"Racioppi A, Dalton T, Ramalingam S, Romero K, Ren Y, Bohannon L, et al. Assessing the feasibility of a novel mHealth app in hematopoietic stem cell transplant patients. Transpl Cell Ther. 2021;27(2):e1811\u20139.","journal-title":"Transpl Cell Ther"},{"key":"788_CR75","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/9781119612780.ch4","volume-title":"Blood and marrow transplantation long-term management: survivorship after transplant","author":"CJ Lee","year":"2021","unstructured":"Lee CJ, Wickline M, Flowers MED. Telemedicine in patient care of long-term transplant survivors. In: Savani BN, Tichelli A, editors. Blood and marrow transplantation long-term management: survivorship after transplant. 2nd ed. Hoboken: Wiley; 2021. pp. 25\u201332.","edition":"2"},{"issue":"7","key":"788_CR76","first-page":"e6161","volume":"27","author":"J Turner","year":"2021","unstructured":"Turner J, He Q, Baker K, Chung L, Lazarevic-Fogelquist A, Bethune D, et al. Home spirometry telemonitoring for early detection of bronchiolitis obliterans syndrome in patients with chronic graft-versus-host disease. Transpl Cell Ther. 2021;27(7):e6161\u20136.","journal-title":"Transpl Cell Ther"},{"issue":"1","key":"788_CR77","doi-asserted-by":"publisher","first-page":"e10","DOI":"10.1016\/S2352-3026(22)00383-9","volume":"10","author":"A G\u00f3mez-De Le\u00f3n","year":"2023","unstructured":"G\u00f3mez-De Le\u00f3n A, Faisal MS. A world, connected. Lancet Haematol. 2023;10(1):e10. https:\/\/doi.org\/10.1016\/S2352-3026(22)00383-9.","journal-title":"Lancet Haematol"},{"key":"788_CR78","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1200\/GO.20.00620","volume":"7","author":"R Demichelis-G\u00f3mez","year":"2021","unstructured":"Demichelis-G\u00f3mez R, Alvarado-Ibarra M, Vasquez-Ch\u00e1vez J, et al. Treating acute leukemia during the COVID-19 pandemic in an environment with limited resources: A multicenter experience in four Latin American countries. JCO Glob Oncol. 2021;7:577\u201384. https:\/\/doi.org\/10.1200\/GO.20.00620.","journal-title":"JCO Glob Oncol"},{"key":"788_CR79","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.2147\/CMAR.S348923","volume":"14","author":"K Hradsk\u00e1","year":"2022","unstructured":"Hradsk\u00e1 K, Popkov\u00e1 T, Sko\u0159upov\u00e1 M, et al. Management of treatment-related infectious complications in high-risk hemato-oncological patients via telemedicine. Cancer Manag Res. 2022;14:1655\u201361. https:\/\/doi.org\/10.2147\/CMAR.S348923.","journal-title":"Cancer Manag Res"},{"issue":"1","key":"788_CR80","doi-asserted-by":"publisher","first-page":"2598719","DOI":"10.1080\/17482631.2025.2598719","volume":"20","author":"D Ghannam","year":"2025","unstructured":"Ghannam D, Angel\u00e9-Halgand N, Kosremelli-Asmar M. Fragmentation of healthcare systems: challenges through patients\u2019 eyes. Int J Qual Stud Health Well-being. 2025;20(1):2598719. https:\/\/doi.org\/10.1080\/17482631.2025.2598719.","journal-title":"Int J Qual Stud Health Well-being"},{"key":"788_CR81","doi-asserted-by":"publisher","first-page":"e2400114","DOI":"10.1200\/GO.24.00114","volume":"10","author":"D Pain","year":"2024","unstructured":"Pain D, MacDuffie E, Martei YM, et al. Barriers to implementing a quality improvement program in low- and middle-income countries: adequacy of resources. JCO Glob Oncol. 2024;10:e2400114. https:\/\/doi.org\/10.1200\/GO.24.00114.","journal-title":"JCO Glob Oncol"},{"key":"788_CR82","doi-asserted-by":"publisher","first-page":"106786","DOI":"10.1016\/j.leukres.2022.106786","volume":"113","author":"C Parker","year":"2022","unstructured":"Parker C, Ayton D, Zomer E, et al. Do patients with haematological malignancies suffer financial burden? A cross-sectional study of patients seeking care through a publicly funded healthcare system. Leuk Res. 2022;113:106786. https:\/\/doi.org\/10.1016\/j.leukres.2022.106786.","journal-title":"Leuk Res"},{"issue":"7","key":"788_CR83","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.jtct.2025.04.015","volume":"31","author":"CT Su","year":"2025","unstructured":"Su CT, Saber W, Bansal A, et al. Out-of-pocket expenditures and financial hardship among patients with myelodysplastic syndrome undergoing allogeneic transplant or hypomethylating agent\/supportive care (BMT CTN 1102). Transpl Cell Ther. 2025;31(7):459. https:\/\/doi.org\/10.1016\/j.jtct.2025.04.015.","journal-title":"Transpl Cell Ther"},{"issue":"19","key":"788_CR84","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1182\/blood.2025029876","volume":"146","author":"A Nazha","year":"2025","unstructured":"Nazha A, Elemento O, Ahuja S, et al. Artificial intelligence in hematology. Blood. 2025;146(19):2283\u201392. https:\/\/doi.org\/10.1182\/blood.2025029876.","journal-title":"Blood"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-026-00788-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11899-026-00788-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-026-00788-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T07:44:17Z","timestamp":1789112657000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11899-026-00788-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,11]]},"references-count":84,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["788"],"URL":"https:\/\/doi.org\/10.1007\/s11899-026-00788-z","relation":{},"ISSN":["1558-822X"],"issn-type":[{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,11]]},"assertion":[{"value":"6 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":1,"name":"Ethics","label":"Ethics Approval and Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"20"}}